Sorin Group S.p.A. Announces Enrollment Of First Patients In The Vanguard Clinical Study
MILAN--(BUSINESS WIRE)--Sorin Group, (Reuters Code: SORN.MI), a global medical device company and a leader in the treatment of cardiovascular diseases, announced today the first successful implants of the EquiliaTM system in the Vanguard (Vagal Nerve Stimulation Safeguarding Heart Failure Patients) clinical study. The system is intended to treat heart failure by stimulating the vagus nerve.
Heart failure has been shown to be associated with an imbalance in the autonomic nervous system that controls cardiac activity. This imbalance, a reduction in parasympathetic activity and an increase in sympathetic activity, overstresses the heart and contributes to the worsening of heart failure1.
Help employers find you! Check out all the jobs and post your resume.
Heart failure has been shown to be associated with an imbalance in the autonomic nervous system that controls cardiac activity. This imbalance, a reduction in parasympathetic activity and an increase in sympathetic activity, overstresses the heart and contributes to the worsening of heart failure1.
Help employers find you! Check out all the jobs and post your resume.